D. Carvalho, Mécanismes de l'alloréactivité, des rejets de greffe, p.12

M. Mohty and D. Olive, Peut-on séparer GVHD et GVT après greffe de cellules souches médecine/sciences, vol.19, p.540541, 2003.

E. H. Warren and H. J. Deeg, Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies, Tissue Antigens, vol.81, p.183193, 2013.

S. J. Lee, High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation, Blood, vol.110, p.45764583, 2007.

M. E. Flowers, Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria, Blood, vol.117, issue.11, p.32143219, 2011.

S. Paczesny, A biomarker panel for acute graft-versus-host disease, Blood, vol.113, issue.2, p.273278, 2009.

D. K. Reichenbach, The IL-33/ST2 axis augments effector T-cell responses during acute GVHDD, Blood, vol.125, p.31833192, 2015.

M. T. Vander-lugt, ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death, N. Engl. J. Med, vol.369, p.529539, 2013.

M. J. Hartwell, An early-biomarker algorithm predicts lethal graft-versus-host disease and survival, JCI Insight, vol.2, p.89798, 2017.

M. A. Zaid, Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT, Blood, vol.129, issue.2, p.2017

J. Yu, Biomarker Panel for Chronic Graft-Versus-Host Disease, J. Clin. Oncol. Off. J. Am

. Soc, Clin. Oncol, vol.34, p.25832590, 2016.

A. , Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.21, p.17391745, 2015.

S. Seo, Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.24, p.678686, 2018.

D. M. Ponce, High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation, Blood, vol.125, issue.1, p.199205, 2015.

R. P. Nelson, Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.20, issue.11, p.18611864, 2014.

, CRYOSTEM

R. Storb, Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia, N. Engl. J. Med, vol.314, p.729735, 1986.

A. Bertaina and M. Andreani, Major Histocompatibility Complex and Hematopoietic Stem Cell Transplantation: Beyond the Classical HLA Polymorphism, Int. J. Mol. Sci, vol.19, issue.2, 2018.

S. Spellman, Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.15, p.856863, 2009.

J. H. Falkenburg, L. Van-de-corput, E. W. Marijt, and E. R. Willemze, Minor histocompatibility antigens in human stem cell transplantation, Exp. Hematol, vol.31, p.743

J. E. Levine, A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study, Lancet Haematol, vol.2, issue.1, pp.21-29, 2015.

S. Paczesny, National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The, Biomarker Working Group Report, vol.21, p.780, 2014.

S. Paczesny, Discovery and validation of graft-versus-host disease biomarkers, Blood, vol.121, p.585594, 2013.

S. Paczesny, Biomarkers for posttransplantation outcomes, Blood, vol.131, p.2193

E. W. Petersdorf, High HLA-DP Expression and Graft-versus-Host Disease, N. Engl. J. Med, vol.373, p.599609, 2015.

R. Kakkar and R. T. Lee, The IL-33/ST2 pathway: therapeutic target and novel biomarker, Nat. Rev. Drug Discov, vol.7, p.827840, 2008.

J. Zhang, ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease, Sci. Transl. Med, vol.7, pp.308-160, 2015.

C. G. Kanakry, E. J. Fuchs, and E. L. Luznik, Modern approaches to HLA-haploidentical blood or marrow transplantation, Nat. Rev. Clin. Oncol, vol.13, issue.1, p.1024, 2016.

L. Brunello, Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients, Ann. Hematol, 2018.

T. M. Robinson, Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?, Blood Adv, vol.2, issue.11, p.11801186, 2018.

S. R. Mccurdy and E. J. Fuchs, Comparable Outcomes for Hematologic Malignancies after HLA

, Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation, Adv. Hematol, vol.2015, p.431923, 2015.

C. G. Kanakry, Plasma-derived proteomic biomarkers in human leukocyte antigenhaploidentical or human leukocyte antigen-matched bone marrow transplantation using posttransplantation cyclophosphamide, Haematologica, vol.102, issue.5, p.932940, 2017.

A. Hanoteau, C. Henin, and M. Moser, L'immunothérapie au service de la chimiothérapie, de nouvelles avancées, MS Médecine Sci. ISSN, vol.32, pp.353-361, 2016.

J. M. Magenau, Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.16, p.907914, 2010.

A. Ramadan, Specifically differentiated T cell subset promotes tumor immunity over fatal immunity, J. Exp. Med, vol.214, p.35773596, 2017.

J. F. Camargo and K. V. Komanduri, Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation, Hematol. Oncol. Stem Cell Ther, vol.10, p.233238, 2017.

S. T. Chan and A. C. Logan, The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters, Blood Rev, vol.31, p.173183, 2017.

V. Mehraj, R. Ponte, and J. Routy, The Dynamic Role of the IL-33/ST2 Axis in Chronic Viralinfections: Alarming and Adjuvanting the Immune Response, vol.9, p.3744, 2016.

T. Nabekura, J. Girard, and L. L. Lanier, IL-33 receptor ST2 amplifies the expansion of NK cells and enhances host defense during mouse cytomegalovirus infection, J. Immunol. Baltim. Md, vol.194, p.59485952, 1950.

M. De-la-fuente, T. T. Macdonald, and M. A. Hermoso, The IL-33/ST2 axis: Role in health and disease, Cytokine Growth Factor Rev, vol.26, p.615623, 2015.

A. M. Ramadan, From proteomics to discovery of first-in-class ST2 inhibitors active in vivo, JCI Insight, vol.3, p.14, 2018.

L. Vrancken, L. Delens, Y. Beguin, F. Baron, and S. Servais, Les lymphocytes T dans la GVHD